Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study on the Effectiveness of OSAG 101 (Theraloc®)in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents

NCT00561691 is registered in ClinicalTrials.gov with Oncoscience AG as lead sponsor.

NCT NCT00561691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00561691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study on the Effectiveness of OSAG 101 (Theraloc®)in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents
Lead sponsor
Oncoscience AG
Phase
Observational
Overall status
Completed
Start date
April 30, 2006
Completion date
January 31, 2012
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse instrinsic ponitine glioma